Sees Revenue of $2.6B-$2.7B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy RXT?
Sees revenue $2.6B-$2.7B, consensus $2.72B. Sees adjusted EBITDA $305M-$315M.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RXT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RXT
Wall Street analysts forecast RXT stock price to fall
3 Analyst Rating
0 Buy
3 Hold
0 Sell
Hold
Current: 2.460
Low
1.30
Averages
1.48
High
1.75
Current: 2.460
Low
1.30
Averages
1.48
High
1.75
About RXT
Rackspace Technology, Inc. is an end-to-end hybrid, hybrid cloud, and artificial intelligence (AI) solutions company. The Company designs, builds, and operates its customers’ cloud environments across all technology platforms, irrespective of technology stack or deployment model. The Company operates through two segments. Its Public Cloud segment is a service-centric, capital-light model providing value-added cloud solutions through managed services, elastic engineering and professional services offerings for customer environments hosted on the Amazon Web Services (AWS), Microsoft Azure and Google Cloud public cloud platforms. Its Private Cloud segment is a technology-forward, capital-intensive model providing managed service offerings for customer environments hosted in one of its data centers as well as in those owned by customers or by third parties. Private Cloud product portfolio includes Programmatic Infrastructure, Cloud Operating Systems, Platform-as-a-Service, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Benzinga Stock Whisper Index Analysis for the Week Ending February 27
- Investor Focus: Benzinga's Stock Whisper Index utilizes proprietary data and pattern recognition each week to highlight five undervalued stocks that deserve attention, aiding investors in uncovering new opportunities amidst information overload.
- Market Dynamics: Despite the multitude of methods available to retail traders, the challenge of sifting through abundant information to identify noteworthy stocks underscores the demand for information aggregation tools in the market.
- Data Source: Benzinga Pro serves as a vital channel for investors to access the latest market dynamics and headlines, reflecting the growing need for high-quality market analysis.
- Future Outlook: Investors should keep an eye on upcoming reports to stay attuned to market trends, as Benzinga's continuous updates will provide users with the latest market information and investment opportunities.
See More
Retail Investors Hype Five Hot Stocks This Week
- Nvidia Price Fluctuation: Despite a 53.88% annual increase, NVDA's post-earnings decline has upset retail investors, with current trading around $185 to $187, indicating a weak short-term price trend that may affect investor confidence.
- Netflix Termination Fee Controversy: NFLX's plan to walk away from the WBD deal could yield a $2.8 billion termination fee; although the stock has declined 12.15% over the past year, its strong short-term performance reflects positive market reaction to strategic decisions.
- AMD Stock Rebound: AMD shares have surged 104.68% over the past year, trading between $201 and $204, showing a strong long-term trend despite weaker short-term performance, indicating investor confidence in future growth.
- Salesforce Market Reaction: CRM's stock has fallen 32.36% over the past year, currently trading between $194 and $201, with retail investors mocking its “dinosaur tech” status, reflecting market skepticism about its innovation capabilities, which may impact future performance.
See More
Kraig Biocraft Laboratories Launches Production Plan
- Production Plan Launch: Kraig Biocraft Laboratories has confirmed that its 2026 production plan has transitioned from roadmap to execution, with the March production run marking the first wave of its multi-ton spider silk scale-up initiative, expected to achieve unprecedented commercial volumes, thereby enhancing the company's market competitiveness.
- Technology Showcase Boosts Visibility: The company's recombinant spider silk technology was featured on the cover of National Geographic, highlighting the scalability of its genetically enhanced silkworm platform and emphasizing its commercialization potential across medical, industrial, and defense sectors, further enhancing brand recognition in the market.
- Enterprise AI Partnership Acceleration: The strategic partnership between Rackspace and Palantir aims to deploy Palantir's Foundry and AI platform into production environments, with plans to scale Palantir-trained engineering teams from 30 to over 250 in the next 12 months, significantly improving operational efficiency for enterprises in regulated industries.
- Strategic Review Sparks Value Enhancement: Ensysce Biosciences has initiated a formal review of strategic alternatives aimed at enhancing shareholder value through potential partnerships and capital formation strategies, and while no timeline has been set, such reviews typically introduce more market opportunities for clinical-stage companies.
See More
Kraig Biocraft Laboratories Launches Production Plan
- Production Plan Launch: Kraig Biocraft Laboratories has confirmed that its 2026 production plan has transitioned from planning to execution, with the March production run marking the first major deployment of its multi-ton spider silk scale-up initiative, expected to achieve unprecedented commercial volumes and enhance the company's market competitiveness.
- Technology Showcase Boosts Visibility: Kraig's recombinant spider silk technology was featured on the cover of the March 2026 issue of National Geographic, demonstrating the scalability and tensile strength of its genetically enhanced silkworm platform, further elevating the company's visibility and market recognition in the biomaterials sector.
- AI Partnership Accelerates Deployment: Rackspace and Palantir's strategic partnership aims to implement Palantir's Foundry and AI platform in production environments within regulated industries, with plans to scale Palantir-trained engineering staff from 30 to over 250 in the next 12 months, driving real-world applications of enterprise AI.
- Strategic Review Sparks Value Enhancement: Ensysce Biosciences has initiated a formal review of strategic alternatives aimed at enhancing shareholder value through potential partnerships, licensing transactions, and capital formation strategies, emphasizing that strategic reviews can provide critical optionality and value unlocking opportunities for clinical-stage companies.
See More
Rackspace Reports Below Consensus Fiscal Guidance and Q4 Results
- Earnings Performance: Rackspace reported an adjusted EPS loss of one cent, better than the analyst consensus estimate of a three-cent loss, while sales reached $683 million, slightly above the expected $672.373 million, indicating weak revenue growth amidst challenging market conditions.
- Declining Revenue Trend: The company experienced a 0.4% year-over-year revenue decline, with its Private Cloud segment seeing a significant 10% drop, highlighting the need for Rackspace to reassess its business strategy to regain competitive advantage in a tough market.
- Pessimistic Future Outlook: Rackspace expects an adjusted EPS loss of 15 to 20 cents for fiscal 2026, far below the market's expectation of a one-cent profit, and forecasts revenue between $2.6 billion and $2.7 billion, which is lower than the consensus estimate of $2.719 billion, reflecting a lack of confidence in future performance.
- Weak Stock Performance: Despite a 5.39% decline in stock value over the past year, Rackspace's shares are trading 144% above the 20-day SMA and 86.7% above the 100-day SMA; however, the recent death cross indicates caution for long-term investors as the stock may face potential pullbacks.
See More
NASDAQ 100 Pre-Market Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator fell by 270.65 points to 24,763.72, indicating a weak market sentiment that could impact investor confidence.
- Active Stocks: Rackspace Technology, Inc. (RXT) traded 5,439,330 shares at $2.09, which is 149.26% above its target price of $1.4, suggesting optimistic market expectations for its future performance.
- NVIDIA Update: NVIDIA Corporation (NVDA) saw a decline of $2.32 to $182.57 with a trading volume of 4,934,151 shares; however, its average recommendation remains in the 'buy range', indicating analysts' positive outlook on its long-term growth.
- Netflix Surge: Netflix, Inc. (NFLX) increased by $6.8 to $91.39 with 3,441,533 shares traded, and its analyst recommendation is also in the 'buy range', reflecting market approval of its content strategy.
See More
Benzinga Stock Whisper Index Analysis for the Week Ending February 27
- Investor Focus: Benzinga's Stock Whisper Index utilizes proprietary data and pattern recognition each week to highlight five undervalued stocks that deserve attention, aiding investors in uncovering new opportunities amidst information overload.
- Market Dynamics: Despite the multitude of methods available to retail traders, the challenge of sifting through abundant information to identify noteworthy stocks underscores the demand for information aggregation tools in the market.
- Data Source: Benzinga Pro serves as a vital channel for investors to access the latest market dynamics and headlines, reflecting the growing need for high-quality market analysis.
- Future Outlook: Investors should keep an eye on upcoming reports to stay attuned to market trends, as Benzinga's continuous updates will provide users with the latest market information and investment opportunities.
See More
Retail Investors Hype Five Hot Stocks This Week
- Nvidia Price Fluctuation: Despite a 53.88% annual increase, NVDA's post-earnings decline has upset retail investors, with current trading around $185 to $187, indicating a weak short-term price trend that may affect investor confidence.
- Netflix Termination Fee Controversy: NFLX's plan to walk away from the WBD deal could yield a $2.8 billion termination fee; although the stock has declined 12.15% over the past year, its strong short-term performance reflects positive market reaction to strategic decisions.
- AMD Stock Rebound: AMD shares have surged 104.68% over the past year, trading between $201 and $204, showing a strong long-term trend despite weaker short-term performance, indicating investor confidence in future growth.
- Salesforce Market Reaction: CRM's stock has fallen 32.36% over the past year, currently trading between $194 and $201, with retail investors mocking its “dinosaur tech” status, reflecting market skepticism about its innovation capabilities, which may impact future performance.
See More
Kraig Biocraft Laboratories Launches Production Plan
- Production Plan Launch: Kraig Biocraft Laboratories has confirmed that its 2026 production plan has transitioned from roadmap to execution, with the March production run marking the first wave of its multi-ton spider silk scale-up initiative, expected to achieve unprecedented commercial volumes, thereby enhancing the company's market competitiveness.
- Technology Showcase Boosts Visibility: The company's recombinant spider silk technology was featured on the cover of National Geographic, highlighting the scalability of its genetically enhanced silkworm platform and emphasizing its commercialization potential across medical, industrial, and defense sectors, further enhancing brand recognition in the market.
- Enterprise AI Partnership Acceleration: The strategic partnership between Rackspace and Palantir aims to deploy Palantir's Foundry and AI platform into production environments, with plans to scale Palantir-trained engineering teams from 30 to over 250 in the next 12 months, significantly improving operational efficiency for enterprises in regulated industries.
- Strategic Review Sparks Value Enhancement: Ensysce Biosciences has initiated a formal review of strategic alternatives aimed at enhancing shareholder value through potential partnerships and capital formation strategies, and while no timeline has been set, such reviews typically introduce more market opportunities for clinical-stage companies.
See More
Kraig Biocraft Laboratories Launches Production Plan
- Production Plan Launch: Kraig Biocraft Laboratories has confirmed that its 2026 production plan has transitioned from planning to execution, with the March production run marking the first major deployment of its multi-ton spider silk scale-up initiative, expected to achieve unprecedented commercial volumes and enhance the company's market competitiveness.
- Technology Showcase Boosts Visibility: Kraig's recombinant spider silk technology was featured on the cover of the March 2026 issue of National Geographic, demonstrating the scalability and tensile strength of its genetically enhanced silkworm platform, further elevating the company's visibility and market recognition in the biomaterials sector.
- AI Partnership Accelerates Deployment: Rackspace and Palantir's strategic partnership aims to implement Palantir's Foundry and AI platform in production environments within regulated industries, with plans to scale Palantir-trained engineering staff from 30 to over 250 in the next 12 months, driving real-world applications of enterprise AI.
- Strategic Review Sparks Value Enhancement: Ensysce Biosciences has initiated a formal review of strategic alternatives aimed at enhancing shareholder value through potential partnerships, licensing transactions, and capital formation strategies, emphasizing that strategic reviews can provide critical optionality and value unlocking opportunities for clinical-stage companies.
See More
Rackspace Reports Below Consensus Fiscal Guidance and Q4 Results
- Earnings Performance: Rackspace reported an adjusted EPS loss of one cent, better than the analyst consensus estimate of a three-cent loss, while sales reached $683 million, slightly above the expected $672.373 million, indicating weak revenue growth amidst challenging market conditions.
- Declining Revenue Trend: The company experienced a 0.4% year-over-year revenue decline, with its Private Cloud segment seeing a significant 10% drop, highlighting the need for Rackspace to reassess its business strategy to regain competitive advantage in a tough market.
- Pessimistic Future Outlook: Rackspace expects an adjusted EPS loss of 15 to 20 cents for fiscal 2026, far below the market's expectation of a one-cent profit, and forecasts revenue between $2.6 billion and $2.7 billion, which is lower than the consensus estimate of $2.719 billion, reflecting a lack of confidence in future performance.
- Weak Stock Performance: Despite a 5.39% decline in stock value over the past year, Rackspace's shares are trading 144% above the 20-day SMA and 86.7% above the 100-day SMA; however, the recent death cross indicates caution for long-term investors as the stock may face potential pullbacks.
See More
NASDAQ 100 Pre-Market Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator fell by 270.65 points to 24,763.72, indicating a weak market sentiment that could impact investor confidence.
- Active Stocks: Rackspace Technology, Inc. (RXT) traded 5,439,330 shares at $2.09, which is 149.26% above its target price of $1.4, suggesting optimistic market expectations for its future performance.
- NVIDIA Update: NVIDIA Corporation (NVDA) saw a decline of $2.32 to $182.57 with a trading volume of 4,934,151 shares; however, its average recommendation remains in the 'buy range', indicating analysts' positive outlook on its long-term growth.
- Netflix Surge: Netflix, Inc. (NFLX) increased by $6.8 to $91.39 with 3,441,533 shares traded, and its analyst recommendation is also in the 'buy range', reflecting market approval of its content strategy.
See More
